ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
NCT06810518
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
- Inflammatory Bowel Syndrome
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- American Laboratory Products Company
- Last updated on ClinicalTrials.gov
- April 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Med-Care Research Corp · Miami, FL
Ohio · 1
- Gastro Intestinal Research Institute of Northern Ohio, · Westlake, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.